Bulletin
Investor Alert

Roche Holding AG Part. Cert.

OTC: RHHVF

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Roche Holding AG Part. Cert.

Market closed

 --Quotes are delayed by 20 min

Dec 3, 2021, 3:44 p.m.

RHHVF
/zigman2/quotes/206948568/delayed

$

396.25

Change

+2.75 +0.70%

Volume

Volume 490

Quotes are delayed by 20 min

/zigman2/quotes/206948568/delayed

Previous close

$ 393.50

$ 396.25

Change

+2.75 +0.70%

Day low

Day high

$391.48

$396.25

Open

52 week low

52 week high

$308.57

$411.44

Open

Company Description

Roche Holding AG operates as a research healthcare company. It operates through the following divisions: Pharmaceuticals and Diagnostics. The Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four busin...

Roche Holding AG operates as a research healthcare company. It operates through the following divisions: Pharmaceuticals and Diagnostics. The Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized & point of care solutions, molecular diagnostics, tissue diagnostics & diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Valuation

P/E Current

22.14

P/E Ratio (with extraordinary items)

22.49

P/E Ratio (without extraordinary items)

18.48

Price to Sales Ratio

4.58

Price to Book Ratio

7.25

Price to Cash Flow Ratio

14.72

Enterprise Value to EBITDA

14.15

Enterprise Value to Sales

5.28

Total Debt to Enterprise Value

0.06

Efficiency

Revenue/Employee

574,809.00

Income Per Employee

140,886.00

Receivables Turnover

4.88

Total Asset Turnover

0.69

Liquidity

Current Ratio

1.30

Quick Ratio

1.01

Cash Ratio

0.49

Profitability

Gross Margin

71.96

Operating Margin

30.40

Pretax Margin

30.80

Net Margin

24.51

Return on Assets

16.89

Return on Equity

41.38

Return on Total Capital

33.25

Return on Invested Capital

30.50

Capital Structure

Total Debt to Total Equity

42.41

Total Debt to Total Capital

29.78

Total Debt to Total Assets

17.89

Long-Term Debt to Equity

30.53

Long-Term Debt to Total Capital

21.44

Officers and Executives

Name Age Officer Since Title
Dr. Severin Schwan 53 2008 Chief Executive Officer
Dr. Alan Hippe 69 2011 Chief Financial Officer
Dr. Gallia G. Levy - - Associate Group Medical Director-Hematology
Ms. Pascale Schmidt 47 2020 Chief Compliance Officer
Dr. William Pao 52 2014 Global Head-Oncology Disease & Translational Area

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
08/12/2021 Executive Officer Swiss
3,163   Disposition at $368.23 per share. 1,164,698
08/09/2021 Executive Officer Swiss
8,788   Acquisition at $362.2 per share. 3,183,013
08/09/2021 DIRECTOR Swiss Non EXECUTIVE
271   Acquisition at $394.4 per share. 106,881
07/30/2021 Executive Officer Swiss
4,317   Disposition at $350 per share. 1,510,950
07/30/2021 Executive Officer Swiss
1,116   Disposition at $350 per share. 390,600
06/22/2021 Executive Officer Swiss
500   Disposition at $374.8 per share. 187,400
06/17/2021 Executive Officer Swiss
3,000   Disposition at $348.6 per share. 1,045,800
06/17/2021 Executive Officer Swiss
2,000   Disposition at $373.13 per share. 746,250
06/11/2021 Executive Officer Swiss
500   Disposition at $366 per share. 183,000
06/08/2021 Executive Officer Swiss
4,057   Disposition at $329.94 per share. 1,338,580
05/11/2021 Executive Officer Swiss
1   Award at $0 per share. 0
05/11/2021 Executive Officer Swiss
1   Acquisition at $499,995 per share. 499,995
05/11/2021 Executive Officer Swiss
1   Acquisition at $137,490 per share. 137,490
05/11/2021 Executive Officer Swiss
1   Acquisition at $93,720 per share. 93,720
03/23/2021 Executive Officer Swiss
1,189   Disposition at $310 per share. 368,590
03/23/2021 Executive Officer Swiss
1,810   Disposition at $310 per share. 561,100
03/02/2021 Executive Officer Swiss
777   Acquisition at $304.35 per share. 236,478
/news/latest/company/us/rhhvf

MarketWatch News on RHHVF

  1. 5 money moves one China basher is making now

    12:51 a.m. May 19, 2011

    - Jonathan Burton

  2. U.S. FDA to rescind Avastin for breast cancer

    12:03 p.m. Dec. 16, 2010

    - Sue Chang

  3. U.S. FDA to rescind Avastin for breast cancer: WSJ

    11:59 a.m. Dec. 16, 2010

    - Sue Chang

  4. Industry moves to self-police drug advertising

    10:21 a.m. July 25, 2005

    - Kristen Gerencher

  5. Experts see holes in FDA drug safety net

    7:50 p.m. Nov. 19, 2004

    - Laura Gilcrest

  6. Drug stocks under pressure, Cap Gemini higher

    11:59 a.m. Nov. 19, 2004

    - Emily Church

  7. Drugmaker stocks in focus, U.S. futures flat

    8:58 a.m. Nov. 19, 2004

    - Emily Church

  8. Genentech subpoenaed over promotion of Rituxan

    9:03 p.m. Oct. 4, 2004

    - Carolyn Pritchard

  9. Court dismisses Promega fraud case vs Roche, ABI

    3:42 p.m. Aug. 23, 2004

    - August Cole

  10. Stocks to watch Thursday

    9:38 p.m. June 16, 2004

    - Carla Mozee

  11. Biogen, Genentech release Phase II data on Rituxan

    4:52 p.m. June 16, 2004

    - Val Brickates Kennedy

  12. Stocks to watch Tuesday: A, NTAP, NFB, GPT, WMT

    8:24 p.m. Feb. 16, 2004

    - Carolyn Pritchard

  13. Stocks to watch Tuesday

    4:06 p.m. Feb. 14, 2004

    - CBS MarketWatch

  14. Government investigating ways to get more flu vaccine

    4:36 p.m. Dec. 10, 2003

    - Kristen Gerencher

  15. Pill-splitting found safe, economical; industry differs

    11:47 p.m. Sept. 2, 2002

    - Andrea Coombes

/news/nonmarketwatch/company/us/rhhvf

Other News on RHHVF

  1. Wide-Moat Stocks On Sale - The December 2021 Heat Map

    6:28 a.m. Nov. 26, 2021

    - Seeking Alpha

  3. VYMI: International High Yield Overweight In Financials

    1:35 a.m. Nov. 6, 2021

    - Seeking Alpha

  4. Biogen: The Price Is Wrong

    7:00 a.m. Oct. 8, 2021

    - Seeking Alpha

  7. Roche Holding (RHHBY) Investor Presentation - Slideshow

    2:43 p.m. Sept. 17, 2021

    - Seeking Alpha

  8. Wide-Moat Stocks On Sale - The September 2021 Heat Map

    7:48 a.m. Sept. 1, 2021

    - Seeking Alpha

  9. Tracking Tweedy Browne Portfolio - Q2 2021 Update

    11:46 p.m. Aug. 19, 2021

    - Seeking Alpha

  10. Wide-Moat Stocks On Sale - The August 2021 Heat Map

    9:48 a.m. July 25, 2021

    - Seeking Alpha

  12. Roche Holding AG 2021 Q2 - Results - Earnings Call Presentation

    9:36 a.m. July 22, 2021

    - Seeking Alpha

  13. BioLineRx: A Top Candidate For A Takeover Before 2022 Ends

    3:12 p.m. June 30, 2021

    - Seeking Alpha

  16. Wide-Moat Stocks On Sale - The July 2021 Heat Map

    6:18 a.m. June 25, 2021

    - Seeking Alpha

  18. AstraZeneca After COVID

    11:04 a.m. May 21, 2021

    - Seeking Alpha

  21. Loading more headlines...

At a Glance

Roche Holding AG

Grenzacherstrasse 124

Basel, Basel-Stadt (Basle Town) 4070

Phone

41 616881111

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

View SEC Filings

Revenue

$58.32B

Net Income

$14.30B

Employees

101,465

Annual Report for RHHVF

/news/pressrelease/company/us/rhhvf

Press Releases on RHHVF

No News currently available for RHHVF

Link to MarketWatch's Slice.